Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 2 of 14, showing 10 Applications out of 131 total, starting on record 11, ending on 20

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

11.

ECCT/20/11/03   IMR-SCD-301
    A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease       
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
Site(s) in Kenya
1. Kenya Medical Research Institute-Kondele Children\'s Hospital (Kisumu county)
2. The Center For Respiratory Disease Research/KEMRI (Nairobi City county)
3. Gertrude\'s Children\'s Hospital (Nairobi City county)
 
24-02-2021 View

12.

ECCT/25/08/03   Cabotegravir + Rilpivirine Lon
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human   Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Aga Khan University Hospital (Nairobi City county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
3. KEMRI-WRP (Kericho county)
4. Kenyatta National Hospital Comprehensive Care Centre (Nairobi City county)
 
15-12-2025 View

13.

ECCT/24/04/04   TNBC
    A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH   PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Nandi county)
3. The Aga Khan University Hospital - Kenya (Nairobi City county)
 
19-09-2024 View

14.

ECCT/22/11/03   BFAST
    A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL)   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
12-04-2023 View

15.

ECCT/22/12/03   heredERA
    A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO + TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER   
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
12-04-2023 View

16.

ECCT/23/10/01   CROSSWALK Chronic (C)
    A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) (CROSSWALK-c)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Doreen Terry Karimi
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
10-01-2024 View

17.

ECCT/09/06/02  
    A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy   plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual   Transmission of HIV-1 In Serodiscordant Couples   
Principal Investigator(s)
1. Lisa Ann Mills
Site(s) in Kenya
Kisumu, Kenya
 
05-07-2012 View

18.

ECCT/15/11/05   FALCI Study
    A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria.   
Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
1. KEMRI Center for Respiratory Diseases Research (Siaya county)
2. KEMRI Walter Reed Kombewa (Kisumu county)
3. KEMRI Kisumu (Kisumu county)
 
01-02-2016 View

19.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
28-07-2016 View

20.

ECCT/18/01/01   Mal 094
    Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age.   
Principal Investigator(s)
1. Aaron Samuels
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral hospital (Siaya county)
2. Ngiya Health Center (Siaya county)
3. Kogelo Health Center (Siaya county)
4. Tingwangi (Siaya county)
5. Mulaha (Siaya county)
6. Nyathengo (Siaya county)
7. Bal Olengo (Siaya county)
 
06-03-2018 View